3SBioTRSBF -2.27%90 Operating Margin % is 69.80% as of Dec. 2025, which is 132% above its 10-year median of 30.07. GuruFocus rates TRSBF with a GF Score™ of 90/100 and a GF Value™ of $1.61 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 936 Biotechnology companies, 3SBio ranks better than 98.72% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. 3SBio's Operating Income for the
six
months ended in Dec. 2025 was $1,322 Mil. 3SBio's Revenue for the
six
months ended in Dec. 2025 was $1,894 Mil. Therefore, 3SBio's Operating Margin % for the quarter that ended in Dec. 2025 was 69.80%.
Good Sign:
3SBio Inc operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for 3SBio's Operating Margin % or its related term are showing as below:
TRSBF'
s Operating Margin % Range Over the Past 10 Years
Min: 24.28 Med: 30.07 Max: 60.08
Current: 60.08
TRSBF's Operating Margin % is ranked better than 98.72% of 936
companies
in the Biotechnology industry
Industry Median: -86.55
vs TRSBF: 60.08
3SBio's 5-Year Average Operating Margin % Growth Rate was 11.80% per year.
3SBio's Operating Income for the
six
months ended in Dec. 2025 was $1,322 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was $1,504 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
3SBio Operating Margin % Related Terms
3SBio Operating Margin % Historical Data
* Premium members only.
The historical data trend for 3SBio's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRSBF vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, 3SBio's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's Operating Margin % distribution charts can be found below:
* The bar in red indicates where 3SBio's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
3SBio's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3SBio (TRSBF) has a Operating Margin % of 69.80% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on 3SBio and its competitors. This is 132% above median its historical median of 30.07. Over the past decade, 3SBio's Operating Margin % has ranged from 24.28 to 60.08. According to the industry distribution chart, 3SBio ranks #12 out of 936 companies in the Biotechnology industry, placing it in the top 1.3%.
Is 3SBio's Operating Margin % too high?
3SBio's current Operating Margin % of 69.80% is 132% above median its 10-year median of 30.07. Over the past 10 years, this metric has ranged from a low of 24.28 to a high of 60.08. Based on the distribution chart, 3SBio ranks #12 out of 936 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3SBio has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #12 out of 936 companies for Operating Margin %. This places 3SBio in the top 1% of its industry — outperforming the majority of peers. Historically, 3SBio's own Operating Margin % has ranged from 24.28 to 60.08 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on 3SBio and its competitors. 3SBio's current Operating Margin % is 69.80%, which is 132% above median its own 10-year median of 30.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (TRSBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.61, compared to a current price of $2.15 — trading 33.5% above its estimated fair value. The current Operating Margin % is 69.80%, which is 132% above median its 10-year median of 30.07. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For 3SBio (TRSBF), the current Operating Margin % is 69.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (TRSBF) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of $2.15 is trading 33.5% above its estimated GF Value™ of $1.61.
GuruFocus considers 3SBio to be Significantly Overvalued.
Key valuation signals for TRSBF:
Operating Margin %: 69.80% (132% above median its 10-year median of 30.07)
GF Value™: $1.61 vs. price of $2.15 (33.5% above fair value)
No single metric tells the full story. See the TRSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score
Get the complete analysis for TRSBF
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRSBF has been successfully added to your 
